Production (Stage)
Channel Therapeutics Corporation
CHRO
$1.22
-$0.0065-0.53%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -197.08% | -- | -10.03% | -61.21% | -53.59% |
| Gross Profit | 197.08% | -- | 10.03% | 61.21% | 53.59% |
| SG&A Expenses | 30.72% | 49.24% | 77.89% | 110.89% | 108.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.21% | 10.33% | 129.26% | 158.91% | 167.64% |
| Operating Income | 5.21% | -10.33% | -129.26% | -158.91% | -167.64% |
| Income Before Tax | 18.00% | -7.78% | -118.91% | -162.31% | -188.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.00% | -7.78% | -118.91% | -162.31% | -188.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.00% | -7.78% | -118.91% | -162.31% | -188.19% |
| EBIT | 5.21% | -10.33% | -129.26% | -158.91% | -167.64% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 74.96% | 72.23% | 28.09% | -11.93% | -70.87% |
| Normalized Basic EPS | 73.70% | 71.04% | 26.66% | -11.93% | -70.87% |
| EPS Diluted | 74.96% | 72.23% | 28.09% | -11.93% | -70.87% |
| Normalized Diluted EPS | 73.70% | 71.04% | 26.66% | -11.93% | -70.87% |
| Average Basic Shares Outstanding | 173.16% | 336.48% | 333.17% | 249.72% | 205.31% |
| Average Diluted Shares Outstanding | 173.16% | 336.48% | 333.17% | 249.72% | 205.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |